2020年8月12日 · Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study. We randomly assigned previously untreated patients with confirmed AML who were ineligible for standard...

2020年8月13日 · In previously untreated patients who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received azacitidine alone.

2023年11月2日 · Clinical data on the synergy of Aza with venetoclax (Ven)-a selective, potent BCL-2 inhibitor-in the treatment of myeloid malignancies and the unmet need in HR MDS provide a rationale to evaluate Ven in combination with Aza in treatment-naive HR MDS.

2024年9月24日 · Venetoclax received full approval in October 2020 for use in older, unfit patients with acute myeloid leukemia (AML) combined with either hypomethylating agents or low-dose cytarabine. This ended a semi-centennial of stalled clinical progress and initiated a new treatment option with proven capacity to enhance response and prolong survival in ...

• Venetoclax-based regimens are associated with significant haematological toxicity. Discuss all dose adjustments with consultant. • Venetoclax or azacitidine should not be interrupted for haematological toxicity during Cycle 1 prior to documentation of marrow response on D21-28. Haematological toxicity Modification Before Complete Remission

2022年11月15日 · Azacitidine (AZA) and venetoclax (VEN) combination is approved in previously untreated acute myeloid leukemia (AML) patients ineligible to intensive chemotherapy (IC). However, AZA-VEN is associated with toxicities that often requires dose reduction (or discontinuation) and may limit triplet combination tolerance.

Azacitidine and venetoclax is a potent combination therapy that offers an opportunity to improve the previously dismal prognosis of these patients. It is a well-tolerated combination therapy for upfront treatment of elderly AML and has been found …

The combination of venetoclax and azacitidine demonstrated greater overall efficacy than azacitidine monotherapy for AML treatment. Notably, combination therapy resulted in a higher frequency of complete remission.

Venetoclax + azacitidine is typically given as a first line therapy to patients who cannot tolerate intensive treatment. The goal of treatment is to help increase blood cell counts and possibly put leukemia into remission.

Phase I Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia